Patents by Inventor Persis Amrolia

Persis Amrolia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric Antigen Receptor (CAR) Comprising A CD19-Binding Domain
    Publication number: 20230220077
    Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.
    Type: Application
    Filed: January 12, 2023
    Publication date: July 13, 2023
    Inventors: Martin Pulé, Leila Mekkaoui, Persis Amrolia, Sara Ghorashian, Anne Kramer, Gordon Cheung
  • Chimeric antigen receptor (CAR) comprising a CD19-binding domain
    Patent number: 11578126
    Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: February 14, 2023
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Leila Mekkaoui, Persis Amrolia, Sara Ghorashian, Anne Kramer, Gordon Cheung
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES AND USES THEREOF
    Publication number: 20220096654
    Abstract: The present disclosure relates to novel pyrrolobenzodiazepine antibody-drug conjugates (PBD-ADCs) and therapeutic uses thereof.
    Type: Application
    Filed: September 22, 2021
    Publication date: March 31, 2022
    Inventors: Patricius Hendrikus Cornelis van Berkel, Persis Amrolia, Kerry Chester, Jenny Yeung
  • CHIMERIC ANTIGEN RECEPTOR (CAR) COMPRISING A CD19-BINDING DOMAIN
    Publication number: 20200140544
    Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.
    Type: Application
    Filed: September 17, 2019
    Publication date: May 7, 2020
    Inventors: Martin Pulé, Leila Mekkaoui, Persis Amrolia, Sara Ghorashian, Anne Kramer, Gordon Cheung
  • Chimeric antigen receptor (CAR) comprising a CD19-binding domain
    Patent number: 10457730
    Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 29, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Martin Pulé, Leila Mekkaoui, Persis Amrolia, Sara Ghorashian, Anne Kramer, Gordon Cheung
  • Chimeric Antigen Receptor (CAR) Comprising a CD19-Binding Domain
    Publication number: 20180044417
    Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1-GY-AFSSS (SEQ ID No. 1); CDR2-YPGDED (SEQ ID No. 2) CDR3-SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1-SASSSVSYMH (SEQ ID No. 4); CDR2-DTSKLAS (SEQ ID No. 5) CDR3-QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 15, 2018
    Inventors: Martin Pulé, Leila Mekkaoui, Persis Amrolia, Sara Ghorashian, Anne Kramer, Gordon Cheung